Test Price
2,800 AED✅ Home Collection Available
KIF1BP Gene Hirschsprung Disease NGS Genetic Test in Dubai | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
A comprehensive next‑generation sequencing analysis of the KIF1BP gene for molecular confirmation of Hirschsprung disease. This test delivers high diagnostic yield for congenital aganglionic megacolon assessment, carrier detection, and familial recurrence stratification within the UAE population.
- ✔ Diagnostic Sensitivity: 99.9% via NGS full‑gene coverage including deep intronic and splice‑site regions.
- ✔ Sample Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM).
- ✔ Post‑Test Support: Telephonic clinical guidance with a consultant medical geneticist for result interpretation.
- ✔ Insurance Facilitation: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This molecular diagnostic assay utilises Illumina®‑based next‑generation sequencing to interrogate the entire coding region, exon‑intron boundaries, and selected deep intronic segments of the KIF1BP gene. Pathogenic variants in KIF1BP are responsible for a subset of syndromic and isolated Hirschsprung disease cases. Variant interpretation follows ACMG/AMP 2015 guidelines, and every report is dual‑signed by board‑certified clinical scientists. Confirmatory Sanger sequencing is performed on all clinically actionable variants.
| Feature | KIF1BP NGS Test | Conventional Sanger Sequencing |
|---|---|---|
| Diagnostic Precision | 99.9% – full gene coverage including deep intronic regions | ~95% – limited to exons, may miss non‑coding variants |
| Methodology | NGS (Illumina platform) with confirmatory Sanger | Sequential single‑exon Sanger sequencing |
| Turnaround Time | 3 – 4 Weeks (comprehensive report) | 4 – 6 Weeks (multiple sequential runs) |
| UAE Insurance Coverage | Direct billing / pre‑approval support available | Often out‑of‑pocket with manual claim submission |
Physician Insight & Safety Protocols
“As a consultant medical geneticist specialising in neurocristopathies, I recognise that pursuing a genetic diagnosis for a child with suspected Hirschsprung disease is a significant step for any family in the UAE. This KIF1BP NGS assay provides high‑resolution molecular confirmation, but results must be interpreted alongside a detailed three‑generation pedigree, clinical examination, and anorectal manometry or rectal biopsy findings. Comprehensive genetic counselling is recommended before and after testing.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Clinical Decision Guidance
⚠️ Important Medication & Treatment Advisory
This genetic test provides diagnostic insight only. Do not alter, stop, or initiate any prescribed medications, dietary regimens, or surgical plans based solely on the test results. All management decisions, including whether to proceed with pull‑through surgery or bowel management programmes, must be made under the direct supervision of a qualified paediatric gastroenterologist or paediatric surgeon.
Patient Safety & Exclusion Criteria
- Exclusion: Inability to obtain a valid whole‑blood sample (EDTA) or extracted DNA due to severe coagulopathy or other contraindications to venipuncture without documented physician clearance.
- Exclusion: Lack of informed consent from a legal guardian (mandatory for all minors per Federal Decree‑Law No. 4 of 2016 on Medical Liability).
- Emergency Warning: If the child develops acute abdominal distension, bilious vomiting, fever, or clinical signs suggestive of enterocolitis or bowel perforation, seek immediate emergency medical attention. This genetic test does not replace urgent clinical or surgical evaluation.
Patient FAQ & Clinical Guidance
1. What exactly does the KIF1BP gene NGS test detect, and how accurate is it?
This test detects single‑nucleotide variants, small insertions or deletions, and copy‑number alterations across the entire KIF1BP gene using next‑generation sequencing. Analytical sensitivity and specificity exceed 99.9% for coding regions and flanking splice sites, with all reported variants independently confirmed by Sanger sequencing prior to clinical reporting.
2. How is the test performed, and what is the expected turnaround time?
A peripheral whole‑blood sample (EDTA, lavender‑top tube) is collected by a certified phlebotomist via our VIP home collection service, or you can visit our Dubai Healthcare City facility. After DNA extraction, library preparation, and bioinformatic analysis, each variant is manually curated by two independent clinical scientists. The full process requires 3 to 4 weeks to ensure rigorous quality control and comprehensive reporting.
3. Is the KIF1BP gene test covered by health insurance in the UAE?
Many UAE insurance plans that include genetic testing benefits cover this KIF1BP NGS test when pre‑authorised. Our team can verify your coverage and manage direct billing through our WhatsApp service at +971 54 548 8731. We recommend confirming eligibility with your insurer before sample collection.
4. Who should consider this KIF1BP genetic test?
This test is indicated for infants, children, or adults with clinical features suggestive of Hirschsprung disease, including chronic constipation since birth, failure to pass meconium within 48 hours, abdominal distension, or a confirmed diagnosis of aganglionosis on rectal biopsy. It is also appropriate for asymptomatic siblings or first‑degree relatives of a proband with a known KIF1BP pathogenic variant for carrier testing and recurrence risk assessment.
UAE Regulatory & Data Privacy Adherence
All genetic data generated by this test is processed and stored within UAE‑based, ISO 9001:2015 certified laboratory facilities (Certificate INT/EGQ/2509DA/3139). We operate in full compliance with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – ensuring your genetic information remains confidential and is used solely for diagnostic purposes.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – governing secure electronic health records and telehealth consultations.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – safeguarding informed consent and clinical accountability throughout the testing pathway.
A mandatory pre‑test genetic counselling session with a board‑certified consultant medical geneticist is required before sample collection to review the family pedigree, discuss the scope of results, and obtain written informed consent.
Clinical & Logistical Metadata
| Test Name | KIF1BP Gene Hirschsprung Disease NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA, Lavender‑Top Tube), Extracted DNA, or FTA Card |
| Methodology Used | Next‑Generation Sequencing (Illumina Platform) with Confirmatory Sanger Sequencing |
| ICD-10-CM Code | Q43.1 (Hirschsprung disease), Z15.89 (Genetic susceptibility to other disease), Z13.71 (Encounter for screening for other genetic diseases) |
| LOINC Code | 81247-6 – Targeted sequence analysis, DNA, blood or tissue |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians